Copenhagen-based Curasight closed 2025 having completed its transition from a predominantly diagnostic-focused company to a clinical-stage radioligand therapy developer. The defining milestone of the year was the initiation of clinical development of uTREAT®, the company’s first-in-class uPAR-targeted radioligand therapy, marked by dosing of the first patient in its phase I glioblastoma trial. Combined with a strengthened capital base and continued validation of uPAR biology and the diagnosis platform uTRACE® to support improved treatment, the company is now positioned for an exciting 2026 which includes expected key clinical readouts. BioStock contacted CEO Ulrich Krasilnikoff for a comment.